CellCentric raises 拢90m to prevent cancer deaths
Cancer-fighting MedTech CellCentric has raised 拢90m in fresh funding. The Series C round will support the advancement of the Cambridge company鈥檚 oral treatment for multiple myeloma, inobrodib. The financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society鈥檚 venture capital … Continue reading CellCentric raises 拢90m to prevent cancer deaths
